Zobrazeno 1 - 10
of 299
pro vyhledávání: '"5α-Reductase inhibitors"'
Publikováno v:
Prostate International, Vol 11, Iss 3, Pp 139-144 (2023)
Background: This study aimed to determine the relationship between resistive indices (RIs) and changes in prostate size after medical treatment in patients with benign prostatic hyperplasia (BPH). Methods: A total of 86 patients with BPH were include
Externí odkaz:
https://doaj.org/article/e93703229fb84646ba0a3fafd81e51c1
Publikováno v:
Journal of Clinical Medicine, Vol 13, Iss 11, p 3052 (2024)
The most common type of alopecia in women is female androgenetic alopecia (FAGA), characterized by progressive hair loss in a patterned distribution. Many oral therapies, including spironolactone (an aldosterone antagonist), androgen receptor blocker
Externí odkaz:
https://doaj.org/article/efc7d646f11a4bb39b55e90589e02a29
Publikováno v:
Uro, Vol 3, Iss 1, Pp 27-39 (2023)
Inhibition of 5α-reductase (5αR), which blocks the conversion of testosterone to its active metabolite, dihydrotestosterone, has been shown to impact further prostate enlargement (benign prostatic hyperplasia, or BPH). Clinical trials of standardiz
Externí odkaz:
https://doaj.org/article/e4f91f72c0a242d5b2005cb37f002743
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jun-Jie Zhang, Xiao Shi, Ting Wu, Meng-Da Zhang, Jin Tang, Guang-Ming Yin, Zhi Long, Le-Ye He, Lin Qi, Long Wang
Publikováno v:
Asian Journal of Andrology, Vol 24, Iss 4, Pp 390-397 (2022)
Postfinasteride syndrome (PFS) is a term coined to characterize a constellation of reported undesirable sexual, physical, and neuropsychiatric side effects. In the present study, we conducted the meta-analysis to demonstrate whether the use of 5α-re
Externí odkaz:
https://doaj.org/article/e18308c18fad432696f34a3c12c34335
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-7 (2020)
Abstract Background 5α-reductase inhibitors (5-ARIs) inhibit the pathway of converting the testosterone to dihydrotestosterone and are widely used in benign prostatic hyperplasia patients. Since androgen receptor activation may play a role in urothe
Externí odkaz:
https://doaj.org/article/303ee4ad2e1449dbabcfb7270a0b9834
Autor:
Lucrezia Greta Armando, Raffaella Baroetto Parisi, Elisa Remani, Mariangela Esiliato, Cristina Rolando, Valeria Vinciguerra, Abdoulaye Diarassouba, Clara Cena, Gianluca Miglio
Publikováno v:
Healthcare, Vol 10, Iss 12, p 2567 (2022)
Background: Pharmacological treatment of benign prostatic hyperplasia (BPH)/benign prostatic obstruction (BPO)-associated lower urinary tract symptoms (LUTS) aims at improving patients’ quality of life by managing urinary symptoms and preventing co
Externí odkaz:
https://doaj.org/article/83ac55397bf34aa4b5aed6417b037e6d
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 34, Iss 1, Pp 1597-1606 (2019)
Prostate cancer (PCa) is the second leading cause of death in men. Apart from androgen receptor, 5α-reductase has also been recognized as a potential target. In this study, a series of androst-17β-amide compounds have been designed and synthesized
Externí odkaz:
https://doaj.org/article/79a3f72b203d40f0b2d9a38dca0cc102